Autonomix Medical stock soars after cancer pain therapy shows quality-of-life gains

Investing.com -- Autonomix Medical Inc (NASDAQ:AMIX) stock surged 95% Monday following the company’s announcement of positive subgroup analysis results from its first-in-human proof-of-concept study for its nerve-targeted ablation therapy for pancreatic cancer pain.

The exploratory analysis showed broad improvements in quality-of-life metrics across various patient subgroups, including those with advanced stage 4 cancer and distant metastases. According to the company, patients with late-stage disease demonstrated substantial symptom improvement of 32.48 points at 4-6 weeks post-procedure, with benefits persisting at the 3-month mark.

Across all responding patients, average symptom scores improved by 14.53 points at 4-6 weeks and 26.07 points at 3 months, while functionality increased by 8.15 and 25.56 points respectively. The company reported that all 3-month results exceeded the threshold for clinically meaningful change established by the European Organisation for Research and Treatment of Cancer (EORTC).

These findings complement previously reported results showing nearly 60% reduction in pain intensity and opioid-free outcomes by 4-6 weeks post-procedure. The company noted that 100% of responding patients were able to discontinue opioid use at 7 days post-procedure, with 73% remaining opioid-free at 4-6 weeks.

"These subgroup findings provide deeper insight into how and why our ablation approach is improving outcomes across varied patient types," said Brad Hauser, President and CEO of Autonomix.

The company indicated these insights will guide its upcoming U.S.-based multicenter clinical study, planned to begin in 2026, which will formally evaluate pain relief and quality-of-life outcomes as endpoints.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.